A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.
Participants > 18 years of age with relapsed and/or refractory (defined as >5% b... [+25]
Active serious infection not controlled by oral or IV antibiotics [+9]